This section aims to publish studies looking at all aspects of the prevention, diagnosis and management of hepatitis in humans as well as related molecular genetics, pathophysiology, and epidemiology
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocellular carcinoma. Treatment with first generation protease inhibitors (PI) + peg-interferon (pegIFN) and ribavirin (RBV...
Citation: BMC Infectious Diseases 2020 20:264